Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: Results from Two Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trials

被引：0

作者：

Silverberg, Jonathan ^{[1
]}

Thaci, Diamant ^{[2
]}

Seneschal, Julien ^{[3
,4
]}

Gold, Linda Stein ^{[5
]}

Blauvelt, Andrew ^{[6
]}

Simpson, Eric ^{[7
]}

Chu, Chia-Yu ^{[8
,9
]}

Liu, Zhuqing ^{[10
]}

Lima, Renata Gontijo ^{[10
]}

Pillai, Sreekumar ^{[10
]}

Guttman-Yassky, Emma ^{[11
]}

机构：

[1] George Washington Univ, Sch Med, Washington, DC USA

[2] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany

[3] Univ Bordeaux, Bordeaux, France

[4] Hosp St Andre, Natl Reference Ctr Rare Skin Disorders, Bordeaux, France

[5] Henry Ford Hlth Syst, Detroit, MI USA

[6] Oregon Med Res Ctr, Portland, OR USA

[7] Oregon Hlth & Sci Univ, Portland, OR USA

[8] Natl Taiwan Univ Hosp, Taipei, Taiwan

[9] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[10] Eli Lilly & Co, Indianapolis, IN USA

[11] Icahn Sch Med Mt Sinai, New York, NY USA

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P075

引用

页码：62 / 62

页数：1

共 50 条

[21] EFFICACY AND SAFETY OF IXEKIZUMAB IN A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 3B CLINICAL TRIAL IN PATIENTS WITH MODERATE-TO-SEVERE GENITAL PSORIASIS
Ryan, C.
Menter, A.
Guenther, L.
Blauvelt, A.
Bissonnette, R.
Yang, F. E.
Bleakman, Potts A.
JOURNAL OF SEXUAL MEDICINE, 2018, 15 (02): : S6 - S7
[22] Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled, Phase 3b Clinical Trial in Patients with Moderate-to-Severe Genital Psoriasis
Ryan, Caitriona
Menter, Alan
Guenther, Lyn
Blauvelt, Andrew
Bissonnette, Robert
Yang, Fan Emily
Bleakman, Alison Potts
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 13 - 14
[23] Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled, phase 3b clinical trial in patients with moderate-to-severe genital psoriasis
Ryan, C.
Menter, A.
Guenther, L.
Blauvelt, A.
Bissonnette, R.
Yang, F. E.
Bleakman, A. Potts
Burkhardt, N.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 42 - 42
[24] A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis
Gooderham, Melinda
Lynde, Charles
Alam, Maryam Shayesteh
Sadick, Neil
Rohan, Craig A.
Werschler, William Philip
Hebert, Adelaide A.
Laquer, Vivian T.
Sauder, Maxwell
Del Rosso, James Q.
Rodgers, Timothy
Tan, Ricardo
Schleicher, Stephen
Murrell, Dedee F.
Fernandez-Penas, Pablo
Reich, Adam
Gkalpakiotis, Spyridon
Ruiz, Juan Ruano
Wollenberg, Andreas
Szepietowski, Jacek C.
Sticherling, Michael
Weyergraf, Ansgar J.
Hadzavdic, Suzana Ljubojevic
Baran, Wojciech
Vilchez, Trinidad Montero
Eniko, Telegdy
Sebastian, Michael
Chaudhry, Sohail
Lee, Zachary
Yu, Danni
Liu, Yi
Waltz, Wang
Gilbert, Jenny
Elko-Simms, Lucinda M.
Fanton, Christie
Jue, Charleen
Tagliaferri, Mary
Zalevsky, Jonathan
Rosmarin, David
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 105 - 107
[25] Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials
Alexis, Andrew F.
Rendon, Marta
Silverberg, Jonathan I.
Pariser, David M.
Lockshin, Benjamin
Griffiths, Christopher E. M.
Weisman, Jamie
Wollenberg, Andreas
Chen, Zhen
Davis, John D.
Li, Meng
Eckert, Laurent
Gadkari, Abhijit
Shumel, Brad
Rossi, Ana B.
Graham, Neil M. H.
Ardeleanu, Marius
JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (08) : 804 - 813
[26] Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis
Guttman-Yassky, Emma
Weidinger, Stephan
Simpson, Eric
Gooderham, Melinda
Irvine, Alan
Spelman, Lynda
Silverberg, Jonathan
Elmaraghy, Hany
DeLuca-Carter, Louise
Piruzeli, Maria Lucia Buziqui
Hu, Chaoran
Yang, Fan Emily
Pierce, Evangeline
Bardolet, Laia
Thaci, Diamant
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II3 - II4
[27] The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study
Zhao, Y.
Wu, L.
Lu, Q.
Gao, X.
Zhu, X.
Yao, X.
Li, L.
Li, W.
Ding, Y.
Song, Z.
Liu, L.
Dang, N.
Zhang, C.
Liu, X.
Gu, J.
Wang, J.
Geng, S.
Liu, Q.
Guo, Y.
Dong, L.
Su, H.
Bai, L.
O'Malley, J. T.
Luo, J.
Laws, E.
Mannent, L.
Ruddy, M.
Amin, N.
Bansal, A.
Ota, T.
Wang, M.
Zhang, J.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 633 - 641
[28] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized Phase 3 clinical trials
Hebert, Adelaide
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan
Pierce, Evangeline
Elmaraghy, Hany
Xu, Wen
Pillai, Sreekumar
Dawson, Zach
Siegfried, Elaine
Weidinger, Stephan
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB159 - AB159
[29] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Hebert, Adelaide A.
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan D.
Pierce, Evangeline
Elmaraghy, Hany
Pillai, Sreekumar
Dawson, Zach
Chen, Sherry
Armengol, Clara
Siegfried, Elaine
Weidinger, Stephan
JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
[30] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Hebert, Adelaide
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan
Pierce, Evangeline
Elmaraghy, Hany
Xu, Wen
Pillai, Sreekumar
Dawson, Zach
Siegfried, Elaine
Weidinger, Stephan
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188

← 1 2 3 4 5 →